SG11201601605YA - Methods of treating fragile x syndrome and related disorders - Google Patents

Methods of treating fragile x syndrome and related disorders

Info

Publication number
SG11201601605YA
SG11201601605YA SG11201601605YA SG11201601605YA SG11201601605YA SG 11201601605Y A SG11201601605Y A SG 11201601605YA SG 11201601605Y A SG11201601605Y A SG 11201601605YA SG 11201601605Y A SG11201601605Y A SG 11201601605YA SG 11201601605Y A SG11201601605Y A SG 11201601605YA
Authority
SG
Singapore
Prior art keywords
syndrome
methods
related disorders
treating fragile
fragile
Prior art date
Application number
SG11201601605YA
Inventor
Yaron Daniely
Dalia Megiddo
Original Assignee
Alcobra Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Alcobra Ltd filed Critical Alcobra Ltd
Publication of SG11201601605YA publication Critical patent/SG11201601605YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11201601605YA 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders SG11201601605YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
PCT/IB2014/002398 WO2015033224A2 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Publications (1)

Publication Number Publication Date
SG11201601605YA true SG11201601605YA (en) 2016-04-28

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201601830PA SG11201601830PA (en) 2013-09-09 2014-09-09 Methods of determining response to therapy
SG11201601605YA SG11201601605YA (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201601830PA SG11201601830PA (en) 2013-09-09 2014-09-09 Methods of determining response to therapy

Country Status (12)

Country Link
EP (2) EP3044589A1 (en)
JP (2) JP2016530536A (en)
KR (2) KR20160086818A (en)
CN (2) CN105517546A (en)
AU (2) AU2014315026A1 (en)
CA (2) CA2923421A1 (en)
EA (2) EA201690557A1 (en)
IL (2) IL244343A0 (en)
MX (2) MX2016003002A (en)
SG (2) SG11201601830PA (en)
TW (2) TW201605443A (en)
WO (2) WO2015033224A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015014835A1 (en) * 2013-07-31 2015-02-05 Basf Se Luminescent diazabenzimidazole carbene metal complexes
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (en) * 2017-03-24 2018-09-14 华东师范大学 A kind of self-closing disease sociability assessment system based on data analysis technique
WO2019197632A1 (en) * 2018-04-13 2019-10-17 Healx Limited Treatment of fragile x syndrome
KR20190121569A (en) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 Pharmaceutical Composition for Improving Fragile X Syndrome Comprising Agmatine or its derivatives
US10813899B2 (en) * 2018-06-07 2020-10-27 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US20230024384A1 (en) * 2020-01-08 2023-01-26 Neuroventi Composition comprising lisuride compound for treating fragile x syndrome or related developmental disorders
KR102398219B1 (en) * 2020-02-07 2022-05-17 주식회사 뉴로벤티 Composition comprising rilmenidine compound for treating fragile x syndrome and related developmental disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (en) 1980-06-30 1986-06-25 Baldacci Lab Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOLIC INTOXICATIONS
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
EA023758B1 (en) * 2009-06-25 2016-07-29 Алкобра Лтд. Use of metadoxine for treating attention deficit/hyperactivity disorder (adhd/add)

Also Published As

Publication number Publication date
MX2016003006A (en) 2016-06-10
TW201605443A (en) 2016-02-16
JP2016530291A (en) 2016-09-29
CN105517546A (en) 2016-04-20
MX2016003002A (en) 2016-09-08
IL244343A0 (en) 2016-04-21
EA201690557A1 (en) 2016-07-29
AU2014315026A1 (en) 2016-03-24
CN105917225A (en) 2016-08-31
AU2014316779A1 (en) 2016-03-17
SG11201601830PA (en) 2016-04-28
KR20160078956A (en) 2016-07-05
WO2015033224A3 (en) 2015-07-02
EA201690559A1 (en) 2016-08-31
JP2016530536A (en) 2016-09-29
CA2923421A1 (en) 2015-03-12
EP3044589A1 (en) 2016-07-20
TW201606304A (en) 2016-02-16
EP3043792A2 (en) 2016-07-20
CA2922901A1 (en) 2015-03-12
IL244453A0 (en) 2016-04-21
KR20160086818A (en) 2016-07-20
WO2015033224A2 (en) 2015-03-12
WO2015035402A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
HK1217908A1 (en) Methods of treating cholangiocarcinoma
HK1225654A1 (en) Compositions and methods for the treatment of presbyopia
HK1218506A1 (en) Methods of treating melanoma
EP2970317A4 (en) Pyrimido-diazepinone compounds and methods of treating disorders
EP2971279A4 (en) Methods and devices for high throughpout purification
EP2979670A4 (en) Elastic structure for absorbent article and method for manufacturing elastic structure for absorbent article
IL244343A0 (en) Methods of treating fragile x syndrome and related disorders
GB201320723D0 (en) Composition and methods of treatment
EP2983657A4 (en) Treatment of gastrointestinal and other disorders
EP2968298A4 (en) Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
HK1224307A1 (en) Protoxin-ii variants and methods of use -ii
SG11201509376PA (en) Glass structures and methods of creating and processing glass structures
PL2824168T3 (en) Method and device for the purification of beeswax
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
EP2968008A4 (en) Devices and methods for suppressing tinnitus
GB2517285B (en) Semiconductor devices and methods of manufacture
HK1220213A1 (en) Methods for treatment of nephrotic syndrome and related conditions
EP2945946A4 (en) Process for the preparation and purification of apixaban
HK1205441A1 (en) Article and method of formation
HK1222389A1 (en) Treatment of pulmonary and other conditions
EP3083251C0 (en) Device and method for the production of structured surfaces
ZA201601121B (en) Processing tomato and methods of producing and using same
ZA201601626B (en) Treatment of gases
HK1206865A1 (en) Semiconductor device and method of manufacturing the semiconductor device
IL243765B (en) Processing tomato and methods of producing and using same